Drugs / IRDye800CW-nimotuzumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04459065 | Sep 2020 → Sep 2026 overdue | lung cancer | University of Saskatchewan | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IRDye800CW-nimotuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04459065 ↗ |
| Modality | Diagnostic / imaging agent | “near infrared imaging probe” NCT04459065 ↗ |
| Route | Intravenous | “infused intravenously over a period of 30 minutes” NCT04459065 ↗ |
| Target | EGFR | “IRDye800CW-nimotuzumab targets cancer cells over-expressing EGFR” NCT04459065 ↗ |